NCT00420381View on ClinicalTrials.gov

Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

December 31, 2014

Conditions
Ovarian CancerNeoplasmsCarcinoma
Interventions
DRUG

enzastaurin

1125 mg loading dose then 500 mg, oral, daily, until progressive disease

Trial Locations (1)

19103

Gynecologic Oncology Group 215-854-0770, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

Eli Lilly and Company

INDUSTRY

NCT00420381 - Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter